Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

  • End date
    Dec 21, 2026
  • participants needed
  • sponsor
    Genzyme, a Sanofi Company
Updated on 7 October 2022
replacement therapy


This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD.

Study details include:

  • Study duration: Screening - up to 4 weeks;
  • Primary Analysis Period (PAP) - 52 weeks;
  • Extended Treatment Period (ETP) - 52 weeks;
  • Extended Long term Treatment Period (ELTP) - 104 weeks; 4-week follow-up period for a total study duration - up to 4.08 years.
  • Treatment duration: Up to 4 years
  • Visit frequency: every other week and potentially every week


Study duration may be variable by country, but until avalglucosidase alfa is approved in the patient's country or up to 4.08 years, whichever comes first.

Condition Glycogen Storage Disease Type II
Treatment avalglucosidase alfa
Clinical Study IdentifierNCT04910776
SponsorGenzyme, a Sanofi Company
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Participants must have confirmed diagnosis of infantile-onset Pompe disease defined as: the presence of 2 lysosomal acid α-glucosidase (GAA) pathogenic variants and a documented GAA deficiency from blood, skin, or muscle tissue; or the presence of 1 GAA pathogenic variant and a documented GAA deficiency from blood, skin and muscle tissue in 2 separate samples (from either 2 different tissues or from the same tissue but at 2 different sampling dates)
Participants must have established cross-reactive immunological material (CRIM) status available prior to enrollment
Participants must have cardiomyopathy at the time of diagnosis: ie, left ventricular mass index (LVMI) equivalent to mean age specific LVMI
+1 standard deviation for participants diagnosed by newborn screening or sibling screening
+2 standard deviation for participants diagnosed by clinical evaluation
Parents or legally authorized representative(s) must be capable of giving signed
informed consent

Exclusion Criteria

Participants with symptoms of respiratory insufficiency, including any ventilation use (invasive or noninvasive) at the time of enrollment
Participants with major congenital abnormality
Participants with clinically significant organic disease (with the exception of symptoms relating to Pompe disease)
Participant who has previously been treated in any clinical trial of avalglucosidase alfa
Participant received enzyme-replacement therapy (ERT) with recombinant human acid α glucosidase (rhGAA) from any source
Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note